Vitiligo outpatient management in the United States: findings from the 2012–2019 National Ambulatory Medical care Survey (NAMCS)
Gaurav N. Pathak,Anurag N. Pathak,Vibha Mital,Jimmy Dhillon,Steven R. Feldman,Babar K. Rao,Gaurav N. PathakAnurag N. PathakVibha MitalJimmy DhillonSteven R. FeldmanBabar K. Raoa Department of Dermatology,Rutgers Robert Wood Johnson Medical School,Piscataway,New Jerseyb Center for Dermatology Research,Department of Dermatology,Wake Forest University School of Medicine,Winston-Salem,North Carolinac Department of Computer Science,Rutgers University School of Arts and Sciences,New Brunswick,New Jerseyd Department of Pathology,Wake Forest University School of Medicine,Winston-Salem,North Carolinae Department of Social Sciences and Health Policy,Wake Forest University School of Medicine,Winston-Salem,North Carolinaf Department of Dermatology,University of Southern Denmark,Odense,Denmarkg Department of Dermatology,Rao Dermatology,Atlantic Highlands,New Jersey
DOI: https://doi.org/10.1080/09546634.2024.2311793
2024-02-13
Journal of Dermatological Treatment
Abstract:Keywords: To the editor, Vitiligo is an autoimmune disorder associated with high psychosocial burden due to the disease's cosmetic disfigurement. Vitiligo affects about 0.16% of people in the United States (US) including nearly 1.52% of children, and disproportionately affects patients with skin of color ( Citation 1 , Citation 2 ). Treatment options are aimed at restoring skin pigmentation and include topical calcineurin inhibitors and corticosteroids and systemic therapies such as oral corticosteroids, minocycline, and cyclosporine ( Citation 3 , Citation 4 ). Despite the availability of treatment options, approximately 50% of patients do not receive any treatment for vitiligo ( Citation 5 ). This study aims to characterize outpatient management of vitiligo in the US utilizing data from the National Ambulatory Medical Care Survey (NAMCS).
dermatology